

Haematologica  
HAEMATOL/2019/237719  
Version 4

Targeted genotyping of circulating tumor DNA for classical Hodgkin  
Lymphoma monitoring: a prospective study

Vincent Camus, Mathieu Viennot, Justine Lequesne, Pierre-Julien  
Viailly, Elodie Bohers, Lucile Bessi, Bénédicte Marcq, Pascaline  
Etancelin, Sydney Dubois, Jean-Michel Picquenot, Elena-Liana  
Veresezan, Marie Cornic, Lucie Burel, Justine Loret, Stéphanie Becker,  
Pierre Decazes, Pascal Lenain, Stéphane Lepretre, Emilie Lemasle,  
Hélène Lanic, Anne-Lise Ménard, Nathalie Contentin, Hervé Tilly,  
Aspasia Stamatoullas, and Fabrice Jardin

Disclosures: Tilly: Gilead: Honoraria; Takeda: Consultancy, Honoraria; Celgene:  
Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory  
committees, Research Funding; Karyopharm: Consultancy, Honoraria, Membership on an  
entity's Board of Directors or advisory committees; Roche: Consultancy, Honoraria,  
Membership on an entity's Board of Directors or advisory committees, Research Funding;  
Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or  
advisory committees; Immunogen: Honoraria. Camus : Gilead : Honoraria – Amgen :  
Honoraria – BMS : Honoraria Jardin: Roche: Honoraria; Janssen: Honoraria; Celgen:  
Honoraria.

Contributions: (I) Conception and design: VC, FJ, AS (II) Administrative support: all authors  
(III) Provision of study materials or patients: VC, JMP, ELV, MC, PL, SL, EL, HL, ALM, NC,  
HT, AS, FJ (IV) Collection and assembly of data: VC, MV, PJV, EB, LB, BM, PE, JMP,  
ELV, MC, LBU, JLO, SB, PD, FJ (V) Data analysis and interpretation: VC, JLE, PJV, EB,  
LB, BM, PE, SD, JMP, ELV, (VI) Manuscript writing: VC, MV, JLE, PJV, FJ, PD, AS (VII)  
Final approval of manuscript: All authors